Оценка результатов хирургического лечения больных раком грудного отдела пищевода после индукционной терапии (стр. 22 )

72.  Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus – Japan Esophageal Society – 2012

73.  Hashiguchi T., Nasu M., Hashimoto T., et al. Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer // Molecular and Clinical Oncology – 2014 – Vol.2 – p.719-724

74.  Hauser C., Patett C., von Schoenfels W., et al. Does neoadjuvant treatment before oncologic esophagectomy affect the postoperative quality of life? A prospective, longitudinal outcome study // Dis. Esophagus – 08/2014

75.  Hihara J, Yoshida K, Hamai Y, et al. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer // Anticancer Res. – 2007 – Vol.27 – p.2597-2603

76.  Hulscher J. B, Tijssen J. G., Obertop H., et al. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis // Ann. rg. – 2001 – Vol.72(1) – p.306-313

77.  Hulscher J. B., van Sandick J., de Boer A. G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus // N. Engl. J. Med. – 2002 – Vol.347 – p.1662–1669

78.  Ide H., Educhi R., Nakamura T., et al. The radical operation of thoracic esophageal cancer with cervical lymph node metastases // Materials of the VII World Congress of the International Society for Diseases of the Esophagus – 1-4/09/1998

79.  Izbicki J. R., Broering D. C., Yekebas E. F., et rgery of the Esophagus. Textbook and Atlas of Surgical Practice // Steinkopff Verlag. – 2009 – 386 p.

80.  Jin H. L., Zhu H., Ling T. S. et al. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis // World J. Gastroenterol. – 2009 – Vol.15(47) – p.5983-5991

81.  Karran A., Blake P., Chan D. et al. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy // Br. rg. – 2014 – Vol.101 – p.502-510

82.  Kaushik N., Khalid A., Brody D., et al. Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer // Ann. rg. – 2007 – Vol.83 – p.2000–2002

83.  Kim T. J., Kim H. Y., Lee K. W., Kim M. S. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy // Radiographics – 2009 – Vol.29 – p.403-421

84.  Kranzfelder M., Schuster T., Geinitz H. et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer // Br. rg. – 2011 – Vol.98 – p.768-783

85.  Kumagai K., Rouvelas I., Tsai J. A. et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers // Br. rg. – 2014 – Vol.101 – p.321-338

86.  Kurokawa Y.,Yoshimura K.,Yamamoto S. et al. Inter-criteria reproducibility of RECIST, WHO, Japanese response criteria for gastric cancer or esophageal cancer: From the response dataset of Japan Clinical Oncology Group (JCOG) phase III trials // Journal of Clinical Oncology / 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition) – Vol.24 – №18 – p.4065

87.  La N., Bhasin D. K., Malik A. K., et al. Optimal number of biopsy specimens in the diagnosis of carcinoma of the oesophagus // Gut. – 1992 – Vol.33 – p.724–726

88.  Lee J. L., Park S. I., Kim S. B., et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma // Ann. Oncol. – 2004 – Vol.15 – p.947-954

89.  Lee M. S., Mamon H. J., Hong T. S. et al. Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer // The Oncologist – 2013 – Vol.18 – p.281–287

90.  Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer // Jpn. J. Clin. Oncol. – 2007 – Vol.37 – №11 – p.829-835

91.  Li H., Zhang Y., Cai H., Xiang J. Pattern of lymph node metastases in patients with squamous cell carcinoma of the thoracic esophagus who underwent three-field lymphadenectomy // rg. Res. – 2007 – Vol.39(1) – p.1-6

92.  Lin J., Zeng R., Cao W., et al. Hot beverage and food intake and esophageal cancer in southern China // Asian Pac. J. Cancer Prev. – 2011 – Vol.12 – p.2189-2192

93.  Lowe V. J., Booya F., Fletcher J. G., et parison of positron emission tomography, computed tomography and endoscopic ultrasound in the initial staging of patients with oesophageal cancer // Molecular Imaging Biol. – 2005 – Vol.7(6) – p.422-430

94.  Luketich J. D., Friedman D. M., Weigel T. L., et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans // Ann. rg. – 1999 – Vol.68 – p.1133–1136

95.  Luketich J. D., Nguyen N. T., Schauer P. R. Laparoscopic transhiatal esophagectomy for Barrett's esophagus with high-grade dysplasia // JSLS – 1998 – Vol.2 – p.75-77

96.  Luketich J. D., Rivera M. A., Buenaventura P. O., et al. Minimally Invasive Esophagectomy. Outcomes in 222 Patients // rg. – 2003 – Vol.238(4) – p.486–495

97.  Lv J., Cao X. F., Zhu B., et al. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma // World J. Gastroenterol. – 2010 – Vol.16 – p.1649-1654

98.  Ma H., Li Y., Ding Z., et al. The clinical significance of subcarinal lymph node dissection in the radical resection of oesophageal cancer // Interact. Cardiovasc. rg. – 2013 – Vol.16(6) – p.839-843

99.  Manabe O., Hattori N., Hirata K., et al. Diagnostic Accuracy of Lymph Node Metastasis Depends on Metabolic Activity of the Primary Lesion in Thoracic Squamous Esophageal Cancer // J. Nucl. Med. – 2013 – Vol.54(5) – p.670-676

100.  Mannath J., Subramanian V., Hawkey C. J., Ragunath K. Narrow band imaging for the characterisation of high grade dysplasia and specialized intestinal metaplasia in Barrett's oesophagus: a metaanalysis // Endoscopy – 2010 – Vol.42(5) – p.351

101.  Mao W. M., Zheng W. H., Ling Z. Q. Epidemiologic Risk Factors for Esophageal Cancer Development // Asian Pacific J. Cancer Prev. – 2011 – Vol.12 – p.2461-2466

102.  Mariette C., Seitz J. F., Maillard E., et rgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901 // J. Clin. Oncol. – 2010 –Vol.28 – p.15S

103.  Matsubara T., Veda M., Vchida C., Takahashi T. Modified Stomach Roll for safer Reconstruction After Subtotal Esophagectomy // rg. Oncol. – 2000 – Vol.74 – №12 – p.1115-1117

104.  McKenzie S., Mailey B., Artinyan A. et al. Improved Outcomes in the Management of Esophageal Cancer with the Addition of Surgical Resection to Chemoradiation Therapy // Annals of Surgical Oncology – 2011 – Vol.18 – p.551-558

105.  Meyers B. F., Downey R. J., Decker P. A., et al, and the American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial // J. Thorac. rg. – 2007 – Vol.133 – p.738–745

106.  Minsky B. bined Modality Therapy for Esophageal Cancer // Sem. Oncol. – 2003. – Vol.30(4) – p.46-55

107.  Minsky B. D., Pajak T. F., Ginsberg R. J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy // J. Clin. Oncol. – 2002 – Vol.20 – p.1167-1174

108.  Morgan M. A., Lewis W. G., Casbard A. et al. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma // British Journal of Surgery. – 2009 – Vol.96 – p. 1300-1307

109.  Muijs C. T., Beukema J. C., Mul V. E. et al. External beam radiotherapy combined with intraluminal brachytherapyin esophageal carcinoma. Radiotherapy and Oncology. – 2012. – Vol. 102. – P. 303–308.

110.  Muro K., Hamaguchi T., Ohtsu A., et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer // Annals of Oncology – 2004 – Vol.15 – p.955–959

111.  Murray L., Romero Y. Role of obesity in Barrett’s esophagus and cancer // Surg. Oncol. Clin. N. Am. – 2009 – Vol.18. – p.439-452

112.  Napier K. J., Scheerer M., Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities // World J. Gastrointest. Oncol. – 2014 – Vol.6 (5) – p.112-120

113.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Esophageal Cancers and Esophagogastric Junction. Version 1.2014.

114.  Nishimaki T., Suzuki T., Kanda T., et al. Extended radical esophagectomy for superficially invasive carcinoma of the esophagus // Surgery – 1999 – Vol.125(2) – p.142-147

115.  Okawa T., Dokiya T., Nishio M., et al. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group // Int. J. Radiat. Oncol. Biol. Phys. – 1999– Vol.45(3) – p.623-628

116.  Oppedijk V., van der Gaast A., van Lanschot J. J., et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials // J. Clin. Oncol. – 2014 – Vol.32 – p.385-391

117.  Orringer M. B., Marshall B., Chang A. C., et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned // Ann Surg. – 2007 – Vol.246(3) – p.363-372

118.  Pennathur A., Gibson M. K., Jobe B. A., Luketich J. D. Oesophageal carcinoma // Lancet – 2013 – Vol.381 – p.400–412